Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the children's cancer group experience

Mitchell S. Cairo, Richard Sposto, Sherrie L. Perkins, Anna T. Meadows, Margo L. Hoover-Regan, James R. Anderson, Stuart E. Siegel, Mark A. Lones, Nicole Tedeschi-Blok, Marshall E. Kadin, Carl R. Kjeldsberg, John F. Wilson, Warren Sanger, Erin Morris, Mark D. Krailo, Jonathan L. Finlay

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Historically, the survival of children and adolescents with Burkitt's and Burkitt-like lymphoma had been poor. Recently, short and intensive chemotherapy appears to have improved disease outcome. We therefore reviewed the results of four successive Children's Cancer Group trials conducted on 470 children with disseminated Burkitt's and Burkitt-like lymphoma. Of the patients studied, the median age was 8 years (0-21 years), the male:female ratio was 4:1, 58% had lactate dehydrogenase (LDH) ≥ 500 IU/I, 23% had M2 or M3 bone marrow (BM), and 12% demon strated central nervous system involvement. In a multivariate analysis, the 4-year event-free survival (EFS) in patients ≥ 15-years-old compared with < 15-year-old was 34 ± 7 versus 59 ± 2% (P < 0.05), the 4-year EFS of M2/M3 compared with M1 BM was 38 ± 5 versus 63 ± 3% (P < 0.001), and the 4-year EFS with LDH ≥ 500 IU/I compared with LDH < 500 IU/I was 49 ± 3 versus 71 ± 4% (P < 0.001). Furthermore, patients treated on the most recent protocol, which was short and more intensive, had a significantly improved survival compared with those on previous trials (4-year EFS 80 ± 6 versus 54 ± 2%, P < 0.001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy.

Original languageEnglish (US)
Pages (from-to)660-670
Number of pages11
JournalBritish Journal of Haematology
Volume120
Issue number4
DOIs
StatePublished - Feb 1 2003

Fingerprint

Burkitt Lymphoma
Disease-Free Survival
L-Lactate Dehydrogenase
Neoplasms
Bone Marrow
Survival
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Multivariate Analysis
Central Nervous System
Drug Therapy
Therapeutics

Keywords

  • Burkitt's
  • Burkitt-like
  • Childhood
  • Lymphoma
  • Outcome

ASJC Scopus subject areas

  • Hematology

Cite this

Cairo, M. S., Sposto, R., Perkins, S. L., Meadows, A. T., Hoover-Regan, M. L., Anderson, J. R., ... Finlay, J. L. (2003). Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the children's cancer group experience. British Journal of Haematology, 120(4), 660-670. https://doi.org/10.1046/j.1365-2141.2003.04134.x

Burkitt's and Burkitt-like lymphoma in children and adolescents : A review of the children's cancer group experience. / Cairo, Mitchell S.; Sposto, Richard; Perkins, Sherrie L.; Meadows, Anna T.; Hoover-Regan, Margo L.; Anderson, James R.; Siegel, Stuart E.; Lones, Mark A.; Tedeschi-Blok, Nicole; Kadin, Marshall E.; Kjeldsberg, Carl R.; Wilson, John F.; Sanger, Warren; Morris, Erin; Krailo, Mark D.; Finlay, Jonathan L.

In: British Journal of Haematology, Vol. 120, No. 4, 01.02.2003, p. 660-670.

Research output: Contribution to journalArticle

Cairo, MS, Sposto, R, Perkins, SL, Meadows, AT, Hoover-Regan, ML, Anderson, JR, Siegel, SE, Lones, MA, Tedeschi-Blok, N, Kadin, ME, Kjeldsberg, CR, Wilson, JF, Sanger, W, Morris, E, Krailo, MD & Finlay, JL 2003, 'Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the children's cancer group experience', British Journal of Haematology, vol. 120, no. 4, pp. 660-670. https://doi.org/10.1046/j.1365-2141.2003.04134.x
Cairo, Mitchell S. ; Sposto, Richard ; Perkins, Sherrie L. ; Meadows, Anna T. ; Hoover-Regan, Margo L. ; Anderson, James R. ; Siegel, Stuart E. ; Lones, Mark A. ; Tedeschi-Blok, Nicole ; Kadin, Marshall E. ; Kjeldsberg, Carl R. ; Wilson, John F. ; Sanger, Warren ; Morris, Erin ; Krailo, Mark D. ; Finlay, Jonathan L. / Burkitt's and Burkitt-like lymphoma in children and adolescents : A review of the children's cancer group experience. In: British Journal of Haematology. 2003 ; Vol. 120, No. 4. pp. 660-670.
@article{8b1f71f0098641e0b03d61dff6a6a0a2,
title = "Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the children's cancer group experience",
abstract = "Historically, the survival of children and adolescents with Burkitt's and Burkitt-like lymphoma had been poor. Recently, short and intensive chemotherapy appears to have improved disease outcome. We therefore reviewed the results of four successive Children's Cancer Group trials conducted on 470 children with disseminated Burkitt's and Burkitt-like lymphoma. Of the patients studied, the median age was 8 years (0-21 years), the male:female ratio was 4:1, 58{\%} had lactate dehydrogenase (LDH) ≥ 500 IU/I, 23{\%} had M2 or M3 bone marrow (BM), and 12{\%} demon strated central nervous system involvement. In a multivariate analysis, the 4-year event-free survival (EFS) in patients ≥ 15-years-old compared with < 15-year-old was 34 ± 7 versus 59 ± 2{\%} (P < 0.05), the 4-year EFS of M2/M3 compared with M1 BM was 38 ± 5 versus 63 ± 3{\%} (P < 0.001), and the 4-year EFS with LDH ≥ 500 IU/I compared with LDH < 500 IU/I was 49 ± 3 versus 71 ± 4{\%} (P < 0.001). Furthermore, patients treated on the most recent protocol, which was short and more intensive, had a significantly improved survival compared with those on previous trials (4-year EFS 80 ± 6 versus 54 ± 2{\%}, P < 0.001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy.",
keywords = "Burkitt's, Burkitt-like, Childhood, Lymphoma, Outcome",
author = "Cairo, {Mitchell S.} and Richard Sposto and Perkins, {Sherrie L.} and Meadows, {Anna T.} and Hoover-Regan, {Margo L.} and Anderson, {James R.} and Siegel, {Stuart E.} and Lones, {Mark A.} and Nicole Tedeschi-Blok and Kadin, {Marshall E.} and Kjeldsberg, {Carl R.} and Wilson, {John F.} and Warren Sanger and Erin Morris and Krailo, {Mark D.} and Finlay, {Jonathan L.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1046/j.1365-2141.2003.04134.x",
language = "English (US)",
volume = "120",
pages = "660--670",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Burkitt's and Burkitt-like lymphoma in children and adolescents

T2 - A review of the children's cancer group experience

AU - Cairo, Mitchell S.

AU - Sposto, Richard

AU - Perkins, Sherrie L.

AU - Meadows, Anna T.

AU - Hoover-Regan, Margo L.

AU - Anderson, James R.

AU - Siegel, Stuart E.

AU - Lones, Mark A.

AU - Tedeschi-Blok, Nicole

AU - Kadin, Marshall E.

AU - Kjeldsberg, Carl R.

AU - Wilson, John F.

AU - Sanger, Warren

AU - Morris, Erin

AU - Krailo, Mark D.

AU - Finlay, Jonathan L.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Historically, the survival of children and adolescents with Burkitt's and Burkitt-like lymphoma had been poor. Recently, short and intensive chemotherapy appears to have improved disease outcome. We therefore reviewed the results of four successive Children's Cancer Group trials conducted on 470 children with disseminated Burkitt's and Burkitt-like lymphoma. Of the patients studied, the median age was 8 years (0-21 years), the male:female ratio was 4:1, 58% had lactate dehydrogenase (LDH) ≥ 500 IU/I, 23% had M2 or M3 bone marrow (BM), and 12% demon strated central nervous system involvement. In a multivariate analysis, the 4-year event-free survival (EFS) in patients ≥ 15-years-old compared with < 15-year-old was 34 ± 7 versus 59 ± 2% (P < 0.05), the 4-year EFS of M2/M3 compared with M1 BM was 38 ± 5 versus 63 ± 3% (P < 0.001), and the 4-year EFS with LDH ≥ 500 IU/I compared with LDH < 500 IU/I was 49 ± 3 versus 71 ± 4% (P < 0.001). Furthermore, patients treated on the most recent protocol, which was short and more intensive, had a significantly improved survival compared with those on previous trials (4-year EFS 80 ± 6 versus 54 ± 2%, P < 0.001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy.

AB - Historically, the survival of children and adolescents with Burkitt's and Burkitt-like lymphoma had been poor. Recently, short and intensive chemotherapy appears to have improved disease outcome. We therefore reviewed the results of four successive Children's Cancer Group trials conducted on 470 children with disseminated Burkitt's and Burkitt-like lymphoma. Of the patients studied, the median age was 8 years (0-21 years), the male:female ratio was 4:1, 58% had lactate dehydrogenase (LDH) ≥ 500 IU/I, 23% had M2 or M3 bone marrow (BM), and 12% demon strated central nervous system involvement. In a multivariate analysis, the 4-year event-free survival (EFS) in patients ≥ 15-years-old compared with < 15-year-old was 34 ± 7 versus 59 ± 2% (P < 0.05), the 4-year EFS of M2/M3 compared with M1 BM was 38 ± 5 versus 63 ± 3% (P < 0.001), and the 4-year EFS with LDH ≥ 500 IU/I compared with LDH < 500 IU/I was 49 ± 3 versus 71 ± 4% (P < 0.001). Furthermore, patients treated on the most recent protocol, which was short and more intensive, had a significantly improved survival compared with those on previous trials (4-year EFS 80 ± 6 versus 54 ± 2%, P < 0.001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy.

KW - Burkitt's

KW - Burkitt-like

KW - Childhood

KW - Lymphoma

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=0345701969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345701969&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04134.x

DO - 10.1046/j.1365-2141.2003.04134.x

M3 - Article

C2 - 12588354

AN - SCOPUS:0345701969

VL - 120

SP - 660

EP - 670

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -